TheraSight® Expression Profiler measures the activity of all human genes (transcriptome). Based on numerous published gene expression signatures, TheraSight® Expression Profiler provides the treating oncologist with a wealth of valuable information for personalized therapeutic decisions.

By TheraSight® Mutation Profiler individual patterns of therapeutically relevant mutations in important cancer-related genes are uncovered. Knowledge of a patient’s individual mutational status is indispensable for a personalized precision oncology treatment approach.

THERASIGHT® Ultraview Profiler, indispensable for an individualized comprehensive precision oncology treatment, is a unique state-of-the-art assay amalgamating the patient’s transcriptome data (TheraSight® Expression Profiler) and therapeutically important mutation data (TheraSight® Mutation Profiler) from Gen Mutation Panels.

Circulating tumor DNA (cfDNA) represents an accurate reflection of a tumor’s mutation pattern in the blood plasma. It is mostly used for real-time response monitoring to targeted drug treatment and as a surrogate analysis of a tumor’s mutational status in cases where no tumor tissue is accessible.

The test serves to determine how the blood is affected by tumor cells. It allows for a molecular-genetic characterization of the tumor disease (real-time liquid biopsy).

Using isolated, living tumor cells, this test determines the response to cytotoxic and biopharmaceutical treatments.